Present Situation of Application on Protease Spectrum Analysis in Breast Cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

ZHANG Yu , GUO Liying

Department of Breast Surgery， The First Affiliated Hospital of Xinjiang Medical University， Urumchi 830054，Xinjiang， China;

Corresponding author：

Keywords：

Breast cancer; Diagnosis; Protease spectrum

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective 　To explore the application status of protease spectrum analysis in breast cancer.
Methods 　The pertinent literatures in recent ten years were screened with key words “breast cancer，diagnosis，and protease spectrum”.
Results 　At present，the candidate markers being identified in enzyme platform were less， such as ITIH4， C3adesArg，C3adesArg△8， haptoglobin-α1，S100-A9， and so on. In addition to S100-A9，the results of markers in the different research institutes were often contradictory. There had been no large-scale applications in clinical research and more further researchs were needed to prove it’s value.
Conclusions 　Breast cancer tissue or cells obviously express chemokines and their receptors which participate the growth， invasion， and metastasis of breast cancer，and many factors influence the activation of their signals. With the development of proteomics research progress of technology and equipment， the improvement of method and more research data， protease spectrum plays an important role in improving the early diagnosis rate of breast cancer.

Citation： ZHANG Yu,GUO Liying,.. Present Situation of Application on Protease Spectrum Analysis in Breast Cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2012, 19(5): 565-569. doi: Copy

1.	Simpson RJ， Bernhard OK， Greening DW， et al. Proteomicsdriven cancer biomarker discovery：looking to the future [J].Curr Opin Chem Biol， 2008， 12(1)：72-77.
2.	Traub F， Feist H， Kreipe HH， et al. SELDI-MS-based expression profiling of ductal invasive and lobular invasive human breast carcinomas [J]. Pathol Res Pract， 2005， 201(12)：763-770.
3.	Nakagawa T， Huang SK， Martinez SR， et al. Proteomic profiling of primary breast cancer predicts axillary lymph node metastasis[J]. Cancer Res， 2006， 66(24)：11825-11830.
4.	Cowherd SM， Espina VA， Petricoin EF 3rd， et al. Proteomic analysis of human breast cancer tissue with laser-capture microdissection and reverse-phase protein microarrays [J]. Clin Breast Cancer， 2004， 5(5)：385-392.
5.	Sanders ME， Dias EC， Xu BJ， et al. Differentiating proteomic biomarkers in breast cancer by laser capture microdissection and MALDI MS [J]. J Proteome Res， 2008， 7(4)：1500-1507.
6.	Umar A， Dalebout JC， Timmermans AM， et al. Method optimisation for peptide profiling of microdissected breast carcinoma tissue by matrix-assisted laser desorption/ionisation-time of flight and matrix-assisted laser desorption/ionisation-time of flight/time of flight-mass spectrometry [J]. Proteomics， 2005， 5(10)：2680-2688.
7.	Leong S， Christopherson RI， Baxter RC. Profiling of apoptotic changes in human breast cancer cells using SELDI-TOF mass spectrometry [J]. Cell Physiol Biochem， 2007， 20(5)：579-590.
8.	Engwegen JY， Gast MC， Schellens JH， et al. Clinical proteomics：searching for better tumour markers with SELDI-TOF mass spectrometry [J]. Trends Pharmacol Sci， 2006， 27(5)：251-259.
9.	Conrads TP， Zhou M， Petricoin EF 3rd， et al. Cancer diagnosis using proteomic patterns [J]. Expert Rev Mol Diagn， 2003，3(4)：411-420.
10.	Good DM， Thongboonkerd V， Novak J， et al. Body fluid proteomics for biomarker discovery：lessons from the past hold the key to success in the future [J]. J Proteome Res， 2007， 6(12)：4549-4555.
11.	de Noo ME， Deelder A， van der Werff M， et al. MALDI-TOF serum protein profiling for the detection of breast cancer [J].Onkologie， 2006， 29(11)：501-506.
12.	Hu Y， Zhang S， Yu J， et al. SELDI-TOF-MS：the proteomics and bioinformatics approaches in the diagnosis of breast cancer[J]. Breast， 2005， 14(4)：250-255.
13.	Laronga C， Becker S， Watson P， et al. SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers [J]. Dis Markers， 2003， 19(4-5)：229-238.
14.	Pusztai L， Gregory BW， Baggerly KA， et al. Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma [J]. Cancer， 2004， 100(9)：1814-1822.
15.	Shin S， Cazares L， Schneider H， et al. Serum biomarkers to differentiate benign and malignant mammographic lesions [J]. J Am Coll Surg， 2007， 204(5)：1065-1071.
16.	Gast MC， van Dulken EJ， van Loenen TK， et al. Detection of breast cancer by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry tissue and serum protein profiling [J]. Int J Biol Markers， 2009， 24(3)：130-141.
17.	Becker S， Cazares LH， Watson P， et al. Surfaced-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) differentiation of serum protein profiles of BRCA-1 and sporadic breast Cancer [J]. Ann Surg Oncol， 2004， 11(10)：907-914.
18.	Belluco C， Petricoin EF， Mammano E， et al. Serum proteomic analysis identifies a highly sensitive and specific discriminatory pattern in stage 1 breast cancer [J]. Ann Surg Oncol， 2007，14(9)：2470-2476.
19.	Paweletz CP， Trock B， Pennanen M， et al. Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF：potential for new biomarkers to aid in the diagnosis of breast cancer [J]. Dis Markers， 2001， 17(4)：301-307.
20.	Bichsel VE， Liotta LA， Petricoin EF 3rd. Cancer proteomics：from biomarker discovery to signal pathway profiling [J]. Cancer J， 2001， 7(1)：69-78.
21.	Li J， Zhang Z， Rosenzweig J， et al. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer [J]. Clin Chem， 2002， 48(8)：1296-1304.
22.	Li J， Orlandi R， White CN， et al. Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry [J]. Clin Chem， 2005， 51(12)：2229-2235.
23.	Mathelin C， Cromer A， Wendling C， et al. Serum biomarkers for detection of breast cancers：A prospective study [J]. Breast Cancer Res Treat， 2006， 96(1)：83-90.
24.	van Winden AW， Gast MC， Beijnen JH， et al. Validation of previously identified serum biomarkers for breast cancer with SELDI-TOF MS：a case control study [J]. BMC Med Genomics，2009， 2：4.
25.	Gonçalves A， Esterni B， Bertucci F， et al. Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy [J].Oncogene， 2006， 25(7)：981-989.
26.	Song J， Patel M， Rosenzweig CN， et al. Quantification of fragments of human serum inter-alpha-trypsin inhibitor heavy chain 4 by a surface-enhanced laser sorption/ionization-based immunoassay[J]. Clin Chem， 2006， 52(6)：1045-1053.
27.	Villanueva J， Shaffer DR， Philip J， et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns [J]. J Clin Invest， 2006， 116(1)：271-284.
28.	Fung ET， Yip TT， Lomas L， et al. Classification of cancer types by measuring variants of host response proteins using SELDI serum assays [J]. Int J Cancer， 2005， 115(5)：783-789.
29.	Sauter ER， Zhu W， Fan XJ， et al. Proteomic analysis of nipple aspirate fluid to detect biologic markers of breast cancer [J]. Br J Cancer， 2002， 86(9)：1440-1443.
30.	张铭娜，徐娟，高燕，等. 血清CA199 在上皮性卵巢癌中的临床意义 [J]. 天津医药， 2009， 37(3)：186-188.
31.	刘斌，孙国荣，王从俊，等. 血清CA153、CA125 及CA19-9检测对乳腺癌的诊断价值 [J]. 中国普外基础与临床杂志，2011， 18(9)：991-992.
32.	Sørlie T， Perou CM， Tibshirani R， et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications [J]. Proc Natl Acad Sci U S A， 2001， 98(19)：10869-10874.
33.	Perou CM， Sørlie T， Eisen MB，et al. Molecular portraits of human breast tumours [J]. Nature， 2000， 406(6797)：747-752.
34.	Brozkova K， Budinska E，Bouchal P， et al. Surface-enhanced laser desorption/ionization time-of-flight proteomic profiling of breast carcinomas identifies clinicopathologically relevant groups of patients similar to previously defined clusters from cDNA expression[J]. Breast Cancer Res， 2008， 10(3)：R48.
35.	Gonçalves A， Charafe-Jauffret E， Bertucci F， et al. Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypes [J]. Mol Cell Proteomics，2008， 7(8)：1420-1433.
36.	Neve RM， Chin K， Fridlyand J， et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes[J]. Cancer Cell， 2006， 10(6)：515-527.
37.	郑弘宇，陈慧菁，吴凡，等. SELDI-TOF-MS 技术筛查预测乳腺癌患者曲妥珠单抗耐药的生物标志物 [J]. 中国肿瘤生物治疗杂志， 2010， 17(4)：368-373.

1. Simpson RJ， Bernhard OK， Greening DW， et al. Proteomicsdriven cancer biomarker discovery：looking to the future [J].Curr Opin Chem Biol， 2008， 12(1)：72-77.
2. Traub F， Feist H， Kreipe HH， et al. SELDI-MS-based expression profiling of ductal invasive and lobular invasive human breast carcinomas [J]. Pathol Res Pract， 2005， 201(12)：763-770.
3. Nakagawa T， Huang SK， Martinez SR， et al. Proteomic profiling of primary breast cancer predicts axillary lymph node metastasis[J]. Cancer Res， 2006， 66(24)：11825-11830.
4. Cowherd SM， Espina VA， Petricoin EF 3rd， et al. Proteomic analysis of human breast cancer tissue with laser-capture microdissection and reverse-phase protein microarrays [J]. Clin Breast Cancer， 2004， 5(5)：385-392.
5. Sanders ME， Dias EC， Xu BJ， et al. Differentiating proteomic biomarkers in breast cancer by laser capture microdissection and MALDI MS [J]. J Proteome Res， 2008， 7(4)：1500-1507.
6. Umar A， Dalebout JC， Timmermans AM， et al. Method optimisation for peptide profiling of microdissected breast carcinoma tissue by matrix-assisted laser desorption/ionisation-time of flight and matrix-assisted laser desorption/ionisation-time of flight/time of flight-mass spectrometry [J]. Proteomics， 2005， 5(10)：2680-2688.
7. Leong S， Christopherson RI， Baxter RC. Profiling of apoptotic changes in human breast cancer cells using SELDI-TOF mass spectrometry [J]. Cell Physiol Biochem， 2007， 20(5)：579-590.
8. Engwegen JY， Gast MC， Schellens JH， et al. Clinical proteomics：searching for better tumour markers with SELDI-TOF mass spectrometry [J]. Trends Pharmacol Sci， 2006， 27(5)：251-259.
9. Conrads TP， Zhou M， Petricoin EF 3rd， et al. Cancer diagnosis using proteomic patterns [J]. Expert Rev Mol Diagn， 2003，3(4)：411-420.
10. Good DM， Thongboonkerd V， Novak J， et al. Body fluid proteomics for biomarker discovery：lessons from the past hold the key to success in the future [J]. J Proteome Res， 2007， 6(12)：4549-4555.
11. de Noo ME， Deelder A， van der Werff M， et al. MALDI-TOF serum protein profiling for the detection of breast cancer [J].Onkologie， 2006， 29(11)：501-506.
12. Hu Y， Zhang S， Yu J， et al. SELDI-TOF-MS：the proteomics and bioinformatics approaches in the diagnosis of breast cancer[J]. Breast， 2005， 14(4)：250-255.
13. Laronga C， Becker S， Watson P， et al. SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers [J]. Dis Markers， 2003， 19(4-5)：229-238.
14. Pusztai L， Gregory BW， Baggerly KA， et al. Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma [J]. Cancer， 2004， 100(9)：1814-1822.
15. Shin S， Cazares L， Schneider H， et al. Serum biomarkers to differentiate benign and malignant mammographic lesions [J]. J Am Coll Surg， 2007， 204(5)：1065-1071.
16. Gast MC， van Dulken EJ， van Loenen TK， et al. Detection of breast cancer by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry tissue and serum protein profiling [J]. Int J Biol Markers， 2009， 24(3)：130-141.
17. Becker S， Cazares LH， Watson P， et al. Surfaced-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) differentiation of serum protein profiles of BRCA-1 and sporadic breast Cancer [J]. Ann Surg Oncol， 2004， 11(10)：907-914.
18. Belluco C， Petricoin EF， Mammano E， et al. Serum proteomic analysis identifies a highly sensitive and specific discriminatory pattern in stage 1 breast cancer [J]. Ann Surg Oncol， 2007，14(9)：2470-2476.
19. Paweletz CP， Trock B， Pennanen M， et al. Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF：potential for new biomarkers to aid in the diagnosis of breast cancer [J]. Dis Markers， 2001， 17(4)：301-307.
20. Bichsel VE， Liotta LA， Petricoin EF 3rd. Cancer proteomics：from biomarker discovery to signal pathway profiling [J]. Cancer J， 2001， 7(1)：69-78.
21. Li J， Zhang Z， Rosenzweig J， et al. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer [J]. Clin Chem， 2002， 48(8)：1296-1304.
22. Li J， Orlandi R， White CN， et al. Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry [J]. Clin Chem， 2005， 51(12)：2229-2235.
23. Mathelin C， Cromer A， Wendling C， et al. Serum biomarkers for detection of breast cancers：A prospective study [J]. Breast Cancer Res Treat， 2006， 96(1)：83-90.
24. van Winden AW， Gast MC， Beijnen JH， et al. Validation of previously identified serum biomarkers for breast cancer with SELDI-TOF MS：a case control study [J]. BMC Med Genomics，2009， 2：4.
25. Gonçalves A， Esterni B， Bertucci F， et al. Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy [J].Oncogene， 2006， 25(7)：981-989.
26. Song J， Patel M， Rosenzweig CN， et al. Quantification of fragments of human serum inter-alpha-trypsin inhibitor heavy chain 4 by a surface-enhanced laser sorption/ionization-based immunoassay[J]. Clin Chem， 2006， 52(6)：1045-1053.
27. Villanueva J， Shaffer DR， Philip J， et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns [J]. J Clin Invest， 2006， 116(1)：271-284.
28. Fung ET， Yip TT， Lomas L， et al. Classification of cancer types by measuring variants of host response proteins using SELDI serum assays [J]. Int J Cancer， 2005， 115(5)：783-789.
29. Sauter ER， Zhu W， Fan XJ， et al. Proteomic analysis of nipple aspirate fluid to detect biologic markers of breast cancer [J]. Br J Cancer， 2002， 86(9)：1440-1443.
30. 张铭娜，徐娟，高燕，等. 血清CA199 在上皮性卵巢癌中的临床意义 [J]. 天津医药， 2009， 37(3)：186-188.
31. 刘斌，孙国荣，王从俊，等. 血清CA153、CA125 及CA19-9检测对乳腺癌的诊断价值 [J]. 中国普外基础与临床杂志，2011， 18(9)：991-992.
32. Sørlie T， Perou CM， Tibshirani R， et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications [J]. Proc Natl Acad Sci U S A， 2001， 98(19)：10869-10874.
33. Perou CM， Sørlie T， Eisen MB，et al. Molecular portraits of human breast tumours [J]. Nature， 2000， 406(6797)：747-752.
34. Brozkova K， Budinska E，Bouchal P， et al. Surface-enhanced laser desorption/ionization time-of-flight proteomic profiling of breast carcinomas identifies clinicopathologically relevant groups of patients similar to previously defined clusters from cDNA expression[J]. Breast Cancer Res， 2008， 10(3)：R48.
35. Gonçalves A， Charafe-Jauffret E， Bertucci F， et al. Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypes [J]. Mol Cell Proteomics，2008， 7(8)：1420-1433.
36. Neve RM， Chin K， Fridlyand J， et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes[J]. Cancer Cell， 2006， 10(6)：515-527.
37. 郑弘宇，陈慧菁，吴凡，等. SELDI-TOF-MS 技术筛查预测乳腺癌患者曲妥珠单抗耐药的生物标志物 [J]. 中国肿瘤生物治疗杂志， 2010， 17(4)：368-373.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Present Situation of Application on Protease Spectrum Analysis in Breast Cancer

Abstract Full text Figures/Tables Video References Cited by

Format

Content